LABU241129P133500
- 16.00
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Trump has promised to significantly reduce corporate taxes! Who are the potential big winners of the tax cuts?
JPMorgan pointed out that companies in the S&P 500 index with an actual tax rate greater than 15% and 80% of revenue coming from the USA are potential beneficiaries of Trump's tax cuts policy, mainly concentrated in the financial and industrial sectors, followed by essential consumer, optional consumer, and medical care sectors.
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Natera Announces Its Prospera Lung Test Has Met Coverage Requirements From The Centers For Medicare & Medicaid Services' Molecular Diagnostics Services Program For Single Lung Transplant Recipients; This Coverage Applies To SLT Patients In The...
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $202
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
How Is The Market Feeling About United Therapeutics?
Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test.
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Gilead Acquires Investigational HIV Vaccine From Spanish Biotech Aelix
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Incyte To Present Late-Breaking Tafasitamab Data In Follicular Lymphoma At ASH 2024 Alongside 20 Oncology Portfolio Updates, Including Phase 3 InMIND Results And Virtual Analyst Event On December 12
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Price Over Earnings Overview: Gilead Sciences